Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Current Assets: 2021-2024

Historic Current Assets for ARS Pharmaceuticals (SPRY) over the last 4 years, with Dec 2024 value amounting to $334.3 million.

  • ARS Pharmaceuticals' Current Assets rose 62.30% to $338.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $338.9 million, marking a year-over-year increase of 62.30%. This contributed to the annual value of $334.3 million for FY2024, which is 44.26% up from last year.
  • ARS Pharmaceuticals' Current Assets amounted to $334.3 million in FY2024, which was up 44.26% from $231.7 million recorded in FY2023.
  • In the past 5 years, ARS Pharmaceuticals' Current Assets registered a high of $334.3 million during FY2024, and its lowest value of $60.7 million during FY2021.
  • Over the past 3 years, ARS Pharmaceuticals' median Current Assets value was $277.7 million (recorded in 2022), while the average stood at $281.2 million.
  • Its Current Assets has fluctuated over the past 5 years, first skyrocketed by 357.27% in 2022, then decreased by 16.56% in 2023.
  • Over the past 4 years, ARS Pharmaceuticals' Current Assets (Yearly) stood at $60.7 million in 2021, then soared by 357.27% to $277.7 million in 2022, then decreased by 16.56% to $231.7 million in 2023, then surged by 44.26% to $334.3 million in 2024.